Inhibition of hyperprogressive cancer disease induced by immune-checkpoint blockade upon co-treatment with meta-tyrosine and p38 pathway inhibitor

Inhibition of hyperprogressive cancer disease induced by immune-checkpoint blockade upon co-treatment with meta-tyrosine and p38 pathway inhibitor

Abstract Background Although immune-checkpoint inhibitors (ICI) are overall promissory for cancer treatment, they entail, in some cases, an undesired side-effect called hyperprogressive-cancer disease (HPD) associated with acceleration of tumor growth and shortened survival. Methods To understand th...

Full description

Bibliographic Details
Main Authors: Daniela R. Montagna, Alejandra Duarte, Paula Chiarella, Bárbara Rearte, Oscar D. Bustuoabad, Mónica Vermeulen, Raúl A. Ruggiero
Format: Article
Language:English
Published: BMC 2022-08-01
Series:BMC Cancer
Subjects:
Hyperprogressive cancer disease
Immune checkpoints inhibitors
Meta-tyrosine
Metastases
Murine tumors
Online Access:https://doi.org/10.1186/s12885-022-09941-2

Internet

https://doi.org/10.1186/s12885-022-09941-2

Similar Items